Literature DB >> 8380291

Immune responses to varicella zoster virus infections in healthy children.

H A Rotbart1, M J Levin, A R Hayward.   

Abstract

The immune responses to varicella zoster virus were studied in 67 otherwise normal children participating in a placebo-controlled trial of acyclovir for the treatment of chickenpox. No differences were observed between acyclovir and placebo groups. Children were studied longitudinally, at onset of chickenpox, and at 1 month, 3 months, 1 year, and 3 years after infection. These data help define the natural history of the immune response to chickenpox in children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380291     DOI: 10.1093/infdis/167.1.195

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Can herpes zoster be prevented?

Authors:  M J Levin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

2.  Acyclovir for childhood chickenpox. No reason not to treat.

Authors:  H H Balfour
Journal:  BMJ       Date:  1995-01-14

3.  Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell-mediated immunity.

Authors:  A Weinberg; A R Hayward; H B Masters; I A Ogu; M J Levin
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

4.  Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures.

Authors:  Y Zhang; M Cosyns; M J Levin; A R Hayward
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 5.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 6.  Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials.

Authors:  Terry P Klassen; Elaine M Belseck; Natasha Wiebe; Lisa Hartling
Journal:  BMC Pediatr       Date:  2002-09-30       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.